Quantification of tear proteins and sPLA2-IIa alteration in patients with allergic conjunctivitis by Li, Kaijun et al.
Quantification of tear proteins and sPLA2-IIa alteration in patients
with allergic conjunctivitis
Kaijun Li, Xialin Liu, Ziyan Chen, Qiang Huang, Kaili Wu
(The first two authors contributed equally to this study)
Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou 510060, China
Purpose: Allergic conjunctivitis (AC) has been reported to induce the instability of the tear film. The tear protein and the
lipid layer play important roles in maintaining the tear film. The aim of this study was to quantify the alteration of the
major tear protein components and a lipid related protein secretory type IIa phospholipase A2 (sPLA2-IIa) in tears of
seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) patients.
Methods: Twenty-one SAC and PAC patients and thirteen normal controls completed a symptom questionnaire and
underwent regular ocular examination. SAC and PAC patients were diagnosed based on the clinical presentation and
elevated serum IgE levels. Schirmer test paper was used to collect tear samples from SAC and PAC patients and normal
controls. Soybean trypsin inhibitor (SBTI) was used as an internal standard to analyze tear samples in 15% SDS–PAGE
gel. Total tear protein and its major components from the SAC and PAC patients and normal controls were quantified by
band densitometry. The major tear protein bands were determined by MALDI-TOF/TOF spectrum analysis. Western blot
was used to detect the content of sPLA2-IIa in tears of allergic conjunctivitis patients and normal controls.
Results: Schirmer test scores were more than 10 mm in all the SAC and PAC patients and control subjects. The tear film
breakup time of SAC and PAC patients was much shorter than that of the normal controls. We obtained 15 bands of tear
protein by one dimensional SDS–PAGE, in which 14 bands were determined by mass-spectrum analysis. The band
densitometry analysis revealed that the total tear protein concentration was much higher in SAC and PAC patients than
in normal controls (p<0.05). The quantity of tear protein band 4 (serum albumin precursor), band 6 (Ig gamma-2), band
9 (leukocyte elastase inhibitor) were also significantly higher in AC patients (p<0.05). Content of sPLA2-IIa, as shown
by western blot, was much higher in AC patients than in controls.
Conclusions: The total tear protein concentration and some of the major tear protein components was increased in tears
of SAC and PAC patients. In addition, the content of sPLA2-IIa in tears of SAC and PAC patients was elevated. The tear
protein changes in SAC and PAC patients may contribute to instability of tear film.
The incidence of ocular allergy has steadily increased in
industrialized nations and in the urban areas of developing
countries  over  the  past  30  years  [1].  Seasonal  allergic
conjunctivitis  (SAC)  and  perennial  allergic  conjunctivitis
(PAC), the most prevalent forms of ocular allergy, can cause
extreme discomfort and interfere significantly with quality of
life, although they are not severe, vision-threatening ocular
diseases.
Allergic  conjunctivitis  (AC)  has  been  reported  to
adversely affect tear film stability [2-4], causing the ocular
allergic  process  to  last  longer  and  recur  more  often,  and
making successful treatment of AC difficult. Studies have
attributed  the  tear  film  instability  in  eyes  with  AC  to
eosinophilic  activation  and  concomitant  release  of
inflammatory mediators, which may damage the conjunctival
epithelial  and  goblet  cells.  As  a  result,  the  alteration  and
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deficiency of the mucin layer cause instability of the tear film
[3,5-7]. The lipid layer and tear protein components also play
an important role in maintaining stability of the tear film.
Changes in the tear film lipid layer that are typical of dry eye
and a significantly thicker tear film lipid layer have been found
in  SAC  patients  without  corneal  fluorescein  staining  [8],
suggesting that the instability of the tear film was caused by
the alterations of the lipid layer. Tear protein profiles have
historically been characterized using gel electrophoresis and
immunoblot, which have shown the major constituents to
include lysozyme, lactoferrin, secretory IgA, Ig E, lipocalin,
serum albumin, transferrin, and lipophilin [9-15]. Although
there is disagreement in the literature regarding the number of
proteins in the tear film and the functions of the individual
proteins,  some  of  these  functions  are  thought  to  play  an
important protective role in the ocular surface defense system.
The purpose of this study was to elucidate the changes in
tear  protein  in  SAC  and  PAC  patients.  We  studied  the
alterations of the major tear protein components in patients
with seasonal and perennial allergic conjunctivitis, using a
new method that we developed for a previous study [16]. This
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2084method is able to quantify proteins in small tear volumes,
using  SDS–PAGE  densitometry  with  soybean  trypsin
inhibitor (SBTI) as an internal standard. Our previous study
demonstrated that this is a useful diagnostic tool for ocular
diseases  characterized  by  tear  protein  changes  [16].
Moreover,  we  specifically  evaluated  the  expression  of
secretory type IIa phospholipase A2 (sPLA2-IIa) by western
blot and qualified the content alteration of sPLA2-IIa, using
same  approach  with  SBTI  as  an  internal  standard.  Lipid-
related protein sPLA2-IIa, an enzyme at high concentration in
tears, is known to be an innate ocular surface barrier against
microbial infection [17-20]. The sPLA2-IIa activity in the
tears of dry eye patients is significantly higher than in tears of
healthy subjects [21].
We quantified 15 tear protein bands in 15% SDS–PAGE
gel, in which 14 bands were determined by mass-spectrum
analysis. With SBTI used as an internal standard, the total tear
protein concentration was much higher in SAC and PAC
patients than in normal controls (p<0.05), and the quantities
of  tear  protein  band  4,  band  6,  and  band  9  were  also
significantly  higher  in  SAC  and  PAC  patients  (p<0.05).
Furthermore, the content of sPLA2-IIa of western blot in SAC
and PAC patients was much higher than that in controls. This
finding clearly showed that the tear protein is altered in SAC
and PAC patients, which further highlights the important role
of tear protein in tear film stability.
METHODS
Subjects:  Twenty-one  patients,  5  males  and  16  females,
diagnosed with SAC or PAC were enrolled in the study. Mean
patient  age  was  25.1±9.0  years  (Range,  18–41  years).
Inclusion criteria were established based on patient history,
clinical signs and symptoms, and the results of prick tests and
determination of serum specific IgE [20-24]. Subjects with
Schirmer test values less than 10 mm were excluded from the
study. Other exclusion criteria included severe ocular allergy,
such as vernal keratoconjunctivitis (VKC), giant papillary
conjunctivitis (GPC), or atopic keratoconjunctivitis (AKC),
as well as other ocular or systemic diseases. Subjects who had
received treatment in the past 2 weeks were also excluded.
Five males and 7 females, with a mean age of age 21.0±1.4
years served as controls. All the control subjects were non-
contact lens wearers, had normal ocular surface, and were
generally healthy. Informed consent was obtained from each
subject, and ethics approval for this work was obtained from
the Zhongshan Ophthalmic Center, Sun Yat-sen University.
All  the  patients  and  controls  completed  a  questionnaire
regarding symptoms. In all patients, tear film qualitative and
quantitative tests were performed.
Ocular  surface  examinations  and  tear  sample  collection:
After completing the symptom questionnaire, patients and
control  subjects  underwent  slit-lamp  examinations,
measurement of tear film breakup time (BUT), and corneal
fluorescein  staining.  Fifteen  minutes  later,  Schirmer  tests
without anesthesia were performed to collect tear samples. As
previously  described  [16],  volumes  of  tears  collected  by
Schirmer test paper were determined by (1) a standard curve
constructed by the amount of 1 mg/ml BSA applied to the
Schirmer test paper against the wetted length of the Schirmer
test paper, and (2) differences in the weight of the Schirmer
filter paper before and after wetting.
Protein sample preparation: Tear samples were taken from
the Schirmer test strip including the flexed part that was in
contact with the conjunctiva. The first 15 mm strip was placed
in a 1.5 ml Nanosep MF 0.2 μm centrifugal device (P/N
ODM02C33; Pall Corporation, Ann Arbor, MI). 150 μl of
100 mM ammonium bicarbonate was added into the device
and incubated at room temperature for 1 h. Then, the tear
protein solution was eluted by centrifugation for 10 min at
14,000×g. The eluted tear protein solutions were stored at
−70 °C and used within 2 months. For western blot, 75 μl tear
protein elution was precipitated by acetone. Briefly, acetone
was added at −20 °C at a volume (300 μl) four times that of
the sample to be precipitated. The tube was vortexed and then
incubated for 60 min at −20 °C. The proteins were pelletized
by centrifuging for 10 min at 14,000×g. The acetone was
removed leaving the protein pellets in the tube.
Quantification of major tear protein components: The major
tear protein components and total tear protein concentrations
were determined by SDS–PAGE with SBTI as an internal
standard as described previously [16]. Briefly, tear proteins
were separated on a 15% separating gel (0.1% SDS, 1.5 M
Tris-HCl, pH 8.8) with a 5% stacking gel on top (0.1% SDS,
0.5  M  Tris-HCl,  pH  6.8),  under  reducing  conditions.
Typically, an 8–10 μl sample solution containing 0.21 μl tears
(calculated from 7 μl tears/10 mm wetted Schirmer test paper)
was loaded. Each experiment was repeated in three gels. After
SDS–PAGE, the gels were stained and de-stained according
to the rapid CBB R250 staining method [12], and SBTI was
added. The total tear protein and its major components from
the AC patients and normal controls were quantified by band
densitometry. Then, the bands were cut and measured by mass
spectrometry.
Identification of the major tear protein by mass spectrometry:
The  protein  identification  was  conducted  as  previously
described methods with modifications [25]. Briefly, for in-gel
digestion, each gel band was excised, dried, digested with
trypsin (sequencing grade; Promega, Madison, WI). Finally,
peptides were eluted and dissolved with 25 mM ammonium
bicarbonate  for  MALDI-TOF/TOF-MS  analysis.  Mixture
solution (2 μl) of digested peptides and matrix (R-Cyano-4-
hydroxycinnamic acid) was applied to an Anchor Chip of
Ultraflex III TOF/TOF mass spectrometer (Bruker, Bremen,
Germany).  The  peptide  mass  fingerprint  (PMF)  data
combined with the corresponding MS/MS spectra data of the
tryptic peptides derived from the gel bands were searched
against protein sequences from the NCBInr 201005 Homo
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Search parameters were set as follows: Enzyme: Trypsin;
Fixed  modifications:  Carbamidomethyl  (C);  Variable
modifications:Oxidation  (M);  Mass  values:  Monoisotopic;
Peptide  Mass  Tolerance:  ±100  ppm;  Fragment  Mass
Tolerance: ±0.5 Da; Max Missed Cleavages: 1.
Western blot analysis: For western blot, a 75 μl tear protein
elution from each subject was precipitated by acetone. Each
sample was then mixed with 20 μl 1× SDS–PAGE sample
buffer and heated to 100 °C for 5 min before loading. By
following the method we used before [25], tear proteins were
separated by SDS–PAGE with an 8% separating gel, then,
electrophoretically transferred to PVDF membranes. Next,
the membrane was incubated with diluted sPLA2-IIa primary
antibody (1:1,000; Abcam Inc., Cambridge, MA) at 4 °C
overnight with constant shaking. Finally, the protein bands on
PVDF  membrane  was  developed  by  a  Phototope-HRP
western blot kit (Cell Signaling Technology, Danvers, MA)
and  photographed  and  analyzed  under  the  Kodak  Image
Station 4000MM platform (Kodak, Rochester, NY).
Statistics: The differences between the tear proteins of the
SAC and PAC patients and normal controls were assessed by
independent sample t-test. For all statistical tests, p<0.05 was
considered significant.
RESULTS
Subject characteristics; questionnaire findings and ocular
surface  examinations:  SAC  and  PAC  results  from  type  I
hypersensitive reactions. Sympotoms include ocular itching,
tearing,  conjunctival  hyperemia,  chemosis,  clear  white
mucoid discharge, and a glassy appearance of the eye. These
symptoms occur chronically in PAC patients. In both forms
of the disease, elevated IgE levels are detected. In this study,
all the SAC and PAC patients were diagnosed depending on
the above clinical presentation and elevated serum IgE levels.
All the SAC and PAC patients complained of itching in both
eyes. The main symptoms present were dry eyes (71.43%),
mucous discharge (52.38%), foreign body sensation(42.86%),
burning  sensation  (38.10%),  aching  (38.10%),  tearing
(33.33%),  and  photophobia  (23.81%).  Eighteen  patients
(85.71%)had allergic rhinitis.
Upon clinical examination, all patients had conjunctival
hyperemia  and  mild-moderate  papillary  hypertrophy.
Conjunctival chemosis was present in 11 patients (52.38%),
and swelling of the eyelids was present in 5 (23.81%). One to
three points of cornea limbus fluorescein staining was seen in
3 patients (14.29%). None of the eyes of the healthy control
subjects had the above signs. None of the eyes of the AC
patients or the control subjects had giant conjunctival papillae,
superficial  punctate  keratitis  (SPK),  conjunctival  scar,  or
meibomian gland disease. All the patients and control subjects
had no positive corneal fluorescein staining. The mean BUT
was 3.9±1.6 s in the SAC and PAC patients, with BUT of less
than 10 s in all patients. All the control subjects had BUT of
more than 10 s. The Schirmer test scores were more than
10 mm in all the AC patients and control subjects.
Comparison of the major tear protein components between
the  allergic  conjunctivitis  patients  and  normal  controls:
Using 15% SDS–PAGE, we obtained 15 high intensive bands
(Figure 1). Of the 15 bands, 14 contained the specific major
protein  components  identified  by  MALDI-TOF/TOF
spectrum  analysis  (Table  1).  For  example,  lactoferrin  (gi|
38154680) was identified as the representative protein in band
3 (Figure 2).
We quantified and compared all the 15 major tear protein
bands (Table 2). The total protein concentrations of the tears
of SAC and PAC patients (12.60±2.93 mg/ml) were much
higher than those of the normal controls (9.80±2.67 mg/ml;
p<0.05). The quantities of the major tear protein bands 4, 6,
and 9 from the SAC and PAC patients’ samples were all
Figure 1. The comparison of the major
tear  protein  components  between
allergic  conjunctivitis  patients  and
normal  controls  using  SBTI  as  an
internal standard. In 15% SDS–PAGE
gel,a 10 μl sample solution containing
400  ng  SBTI  and  0.21  μl  tears  from
allergic  conjunctivitis  patients  (A)  or
normal controls (B) was loaded. C: The
comparison of tear protein profiles from
allergic  conjunctivitis  patients  and
normal  controls  (solid  line,  tears
collected from normal controls; dotted
line,  tears  collected  from  allergic
conjunctivitis  patients).  Tear  samples
were collected by Schirmer test paper
without  anesthesia.  (B1,  Band1;  B2,
Band2; B3, Band3; and, so forth).
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(p<0.05). When we compared the percentages of each band to
the total protein, the percent contents of bands 1, 3, and 15
were much lower in the SAC and PAC patients’ samples, but
the percent content of band 4 was higher in the samples of
SAC and PAC patients.
sPLA2-IIa changed in tears of allergic conjunctivitis patients:
Western blot analysis showed the expression of sPLA2-IIa in
tears. In isovolumetric tears, the content of sPLA2-IIa in SAC
and  PAC  patients  was  increased  compared  to  that  of  the
normal  controls  (Figure  3;  p<0.05).  Considering  the
differences  in  total  tear  protein  concentration  between
individuals, we calculated the densitometric value of sPLA2-
IIa  in  per  unit  mass  of  tear  protein  by  dividing  the
densitometric value of sPLA2-IIa band by the corresponding
total  tear  protein  concentration.  This  enabled  accurate
quantification of sPLA2-IIa and accurate comparison between
the two groups. The result still showed that the content of
sPLA2-IIa in tears of AC patients (2591.84±2007.49) was
higher than that of the normal controls (1016.25±1013.17,
p=0.017).
DISCUSSION
Tear film instability has been extensively reported in patients
with AC [2-4], and changes in tear protein concentrations are
significantly associated with tear film instability. The up- or
down-regulation of these tear proteins may be indicative of
disease mechanisms. In this study, we measured and analyzed
the alterations of the major tear protein components in patients
with SAC and PAC by using SBTI, which was identified as a
very suitable internal standard to quantify protein levels by
SDS–PAGE densitometry in our previous study [16]. We
TABLE 1. PROTEINS IDENTIFIED BY MALDI-TOF/TOF.
Band
number
Accession
number (gi)*
Protein name Obs. Mr
(kDa)
Theo.
Mr
(kDa)
Matched
peptides
Score Expect Seq.
Cov.
(%)**
1 194595509 spectrin alpha chain, brain isoform
1
96.05 285.72 18 77 0.0041 8
2 23307793 Serum albumin precursor 84.46 71.34 7 70 0.021 12
3 38154680 Lactoferrin 74.21 79.81 19 358 3.4e-031 30
4 6013427 Serum albumin 66.50 71.18 12 317 4.3e-027 16
5 70058 Ig alpha-2 chain C region 62.45 37.35 3 66 0.052 14
6 25987833 Ig gamma-2 heavy chain constant
region
57.97 36.36 6 92 0.00012 20
7 4503571 alpha-enolase 54.62 47.48 11 128 3.4e-008 25
8 14250401 actin, beta 50.30 41.32 15 352 1.4e-030 46
9 13489087 leukocyte elastase inhibitor 47.43 42.83 5 93 0.00012 16
10 4502101 annexin A1 37.48 38.92 4 74 0.0084 14
11 125145 Ig kappa chain C region 29.42 11.77 2 126 5.4e-008 32
13 4504963 Lipocalin-1 precursor 17.06 19.41 5 230 2.2e-018 26
14 4504963 Lipocalin-1 precursor 16.40 19.41 1 49 0.0021 6
15 4557894 Lysozyme precursor 12.71 16.98 7 258 3.4e-021 35
        The asterisk indicates the accession number (gi) was according to the NCBInr201005 database and the double asterisk indicates
        the amino acid sequence coverage for the identified proteins; Ig: Immunoglobulin.
Figure 2. The MALDI-TOF/TOF spectrum analysis of band 3 identified as lactoferrin (gi|38154680). A: The PMF (Peptide Mass Fingerprint)
signals. B: The MS/MS spectra corresponding to one of the parent ions (1460.8448).
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2087found that total tear protein concentrations and some of the
major tear components were increased in our SAC and PAC
patients as compared to the healthy controls.
SAC  and  PAC  are  typical  mast  cell-mediated
hypersensitivity  reactions  [26-28].  The  activation  of  mast
cells leads to the release of powerful vasoactive amines that
are  responsible  for  the  vasodilatation  and  increased
permeability of blood vessels. In addition, the activated mast
cells  can  recruit  eosinophils  to  participate  in  the  allergic
reaction [29]. Conjunctival epithelium and corneal epithelium
are also involved in the pathogenesis of AC. Due to these
changes of the ocular surface in AC, tear protein is altered.
Previous studies have shown that some specific tear proteins,
such as IgE, eosinophil major basic protein, and eosinophil
cationic  protein,  are  increased  in  tears  of  AC  patients
[13-15,30,31].
From a proteomic perspective, this study verified the
alteration  of  tear  protein  components  of  SAC  and  PAC
patients. Literature reports have identified 10 or 11 protein
bands  of  human  tear  by  one  dimensional  SDS–PAGE
TABLE 2. COMPARISON OF THE MAJOR TEAR PROTEIN COMPONENTS FROM ALLERGIC CONJUNCTIVITIS PATIENTS AND NORMAL CONTROLS.
Band
number
Protein name Normal controls (n=12, in
mg/ml)
Allergic conjunctivitis
patients (n=21,in mg/ml)
p-value
1 spectrin alpha chain, brain isoform 1 0.20±0.06 (2.19%) 0.20±0.06(1.67%) 0.843
2 Serum albumin precursor 0.17±0.05(1.93%) 0.22±0.12(1.75%) 0.095
3 Lactoferrin 1.77±0.47(18.18%) 1.96±0.28(15.96%) 0.219
4 Serum albumin 0.66±0.46(6.66%) 1.43±0.82(10.73%) 0.005*
5 Ig alpha-2 chain C region 0.90±0.48(8.76%) 1.07±0.45(8.29%) 0.324
6 Ig gamma-2 heavy chain C-region 0.23±0.10(2.52%) 0.45±0.27(3.36%) 0.003*
7 alpha-enolase 0.15±0.05(1.55%) 0.19±0.08(1.52%) 0.090
8 actin, beta 0.25±0.07(2.63%) 0.30±0.10(2.42%) 0.149
9 leukocyte elastase inhibitor 0.13±0.04(1.37%) 0.20±0.09(1.55%) 0.003*
10 annexin A1 0.15±0.04(1.63%) 0.18±0.10(1.40%) 0.235
11 Ig kappa chain C region 0.82±0.40(8.10%) 1.18±0.59(9.01%) 0.067
12 - 0.67±0.40(6.46%) 0.89±0.27(7.19%) 0.064
13 Lipocalin-1 precursor 1.52±0.65(15.62%) 1.83±0.44(14.96%) 0.118
14 Lipocalin-1 precursor 0.33±0.16(3.34%) 0.42±0.12(3.35%) 0.089
15 Lysozyme precursor 1.72±0.40(17.87%) 1.90±0.29(15.59%) 0.151
Other Bands   0.11±0.08(1.26%) 0.17±0.18(1.23%) -
SUM**   9.80±2.67 12.60±2.93 0.010#
        Values are presented as mean ±standard deviation (%). The asterisk indicfates that the percentages were determined by: Tear
         protein band quantities/SUM*100%. The double asterisk indicates the SUM (the total tear protein concentration) was the sum
        of individual bands. The sharp (hash mark) indicates that p-values were determined by independent sample t-test. A p<0.05 was
        considered significant.
Figure 3. Quantification of sPLA2-IIa in
tears of allergic conjunctivitis patients
and normal controls. A: SDS–PAGE of
tear samples with SBTI as an internal
standard. B: western blot of sPLA2-IIa
in corresponding tear samples. Lanes 1–
4 were from the normal controls and
lanes  5–8  were  from  the  allergic
conjunctivitis patients. C: The first two
columns standard for the densitometric
value  of  sPLA2-IIa  band.  SUM  (the
total tear protein concentration) was the
sum of individual bands, determined by
SDS–PAGE with SBTI as an internal
standard. sPLA2-IIa / SUM means the
relative content of sPLA2-IIa in per unit
mass  of  tear  protein.  Statistical
significant differences were marked by
an asterisk.
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2088electrophoresis [12,32]. In this study, we obtained 15 bands
by  15%  separating  SDS–PAGE.  The  major  protein
component  of  14  bands  have  been  determined  by  mass-
spectrum  analysis  (Table  1).  Our  identified  proteins  are
similar to the band proteins in SDS–PAGE gel reported by Li
and colleagues [32]. We obtained a lower molecular weight
of  the  immunoglobulin  proteins  compared  with  their
appearance  (band  6)  on  the  gel  where  the  heavy  chain
appeared approximately 56 kDa and the light chain around
29 kDa because our MS peaks/data only matched the constant
region  of  immunoglobulin  chain,  but  not  the  “variable”
region.
The increases in total tear protein concentration and some
of the major tear components could be due in part to the
leakage of serum protein (band 4) and the increased local
production  induced  by  allergic  reaction.  There  is  a
significantly increased intensity of band 4 (serum protein),
band  6  (Ig  gamma-2),  and  band  9  (leukocyte  elastase
inhibitor) in SAC and PAC patients. Ballow et al. [33,34]
showed that VKC and GPC patients had normal levels of tear
lysozyme  (band  15),  but  that  the  tear  concentration  of
lactoferrin  (band  3)  was  reduced  both  in  VKC  and  GPC
patients. In our study, we did not find the tear concentration
of either lactoferrin (band 3) or lysozyme (band 15) to be
changed in the SAC/PAC patients. Interestingly, when we
compared the percentages of each band to the total protein,
the percent content of bands 3 and 15 were much lower in AC
patients’  samples  than  in  the  normal  controls.  To  our
knowledge, there are no other published reports about the
changes in concentration of lysozyme and lactoferrin in SAC
and PAC patients.
Moreover, in this study, we specifically evaluated the
Spla2-IIa expression by combined immunoblotting analysis
and band densitometry with SBTI as an internal standard. Our
finding of increased sPLA2-IIa expression in SAC and PAC
patients is in agreement with the study by Chen et al., which
demonstrated that sPLA2-IIa is an inflammatory mediator
when  the  ocular  surface  is  compromised  [21].  The  lipid-
related  protein  sPLA2-IIa  generates  the  precursors  of
proinflammatory lipid mediators, such as free arachidonic
acid and lysophospholipids. sPLA2-IIa plays an important
role in modulating the pathogenesis of many inflammation-
related diseases through its catalytic and non-catalytic activity
[35-40]. In the ocular surface, sPLA2-IIa has two major roles:
the remarkable bactericidal action [18-20], and involvement
in the inflammatory process in a compromised ocular surface
[21]. It is possible that sPLA2-IIa could contribute to the
instability of tear film by disturbing the tear lipid metabolism
and amplifying inflammation in AC patients.
Studies have attributed the tear film instability in eyes
with AC to damaged conjunctival epithelial and goblet cells,
as well as to mucin layer alteration [3,5-7]. Suzuki et al. [8],
however, studied a group of SAC patients without corneal
fluorescein staining and found that 78% of the patients with
SAC  had  dry  eye  changes  in  tear  film  lipid  layer  and
significantly greater thickness of the tear film lipid layer.
Patients in our study had normal Schirmer test scores and no
obvious ocular surface damage, suggesting that the instability
of tear film found in our study might be also associated with
the alterations of the lipid layer. The findings in the current
study, as well as in previous reports, suggest that in the early
phase of AC without ocular epithelial damage, the tear film
instability is caused by the change of tear proteins and the lipid
layer. With development of the disease and resultant ocular
surface damage, a combination of all these factors could cause
an increased instability of the tear film. Moreover, tear film
instability will exacerbate ocular surface damage, comprising
a vicious cycle. This could explain why many patients with
chronic AC have dry eye symptoms and signs. Interruption of
the  vicious  cycle  would  provide  a  new  strategy  for  the
treatment of allergic conjunctivitis.
Usually, the diagnosis of allergic eye diseases is based
entirely on clinical features, which might result in the use of
inappropriate  or  unsuccessful  treatments.  Investigations,
including our current study, have documented the alteration
of tear protein in SAC and PAC, explored the underlying
pathogenic mechanisms of allergic eye disease, and extended
our  knowledge  of  the  cellular  and  mediator  mechanisms
involved. Using a new approach with SBTI as an internal
standard,  we  showed  that  part  of  the  major  tear  protein
components increased in tears of AC patients and further
demonstrated that the sPLA2-IIa expression is increased in
the  AC  patients.  Further  elucidation  of  tear  core  protein
alteration, as well as the related function in tear film stability,
of AC patients will allow a clearer understanding of the ocular
allergic disease processes, leading to the development of more
effective treatments.
ACKNOWLEDGMENTS
The authors gratefully acknowledge Xiancai Lin, Jiangang
Xu, Xueying ZhongLiu, and Huijing Ye in the Zhongshan
Ophthalmic  Center  for  their  assistance  in  tear  sample
collection.  This  study  was  supported  in  part  by  the
“Fundamental Research Funds of State Key Lab” and grant
from  the  Department  of  Science  and  Technology  of
Guangzhou to Kaili Wu (No. 2007 J1-C0101) and a New
Century Excellent Talents in University Research Award in
China to Xialin Liu (No. NCET08–0586).
REFERENCES
1. Riedi CA, Rosario NA. Prevalence of allergic conjunctivitis: a
missed  opportunity?  Allergy  2010;  65:131-2.  [PMID:
20078506]
2. Toda I, Shimazaki J, Tsubota K. Dry eye with only decreased
tear  break-up  time  is  sometimes  associated  with  allergic
conjunctivitis.  Ophthalmology  1995;  102:302-9.  [PMID:
7862418]
Molecular Vision 2010; 16:2084-2091 <http://www.molvis.org/molvis/v16/a224> © 2010 Molecular Vision
20893. Lobefalo L, D'Antonio E, Colangelo L, Della Loggia G, Di
Gioacchino M, Angelucci D, Di Iorio A, Gallenga PE. Dry
eye in allergic conjunctivitis: role of inflammatory infiltrate.
Int  J  Immunopathol  Pharmacol  1999;  12:133-7.  [PMID:
12783641]
4. Berdy GJ, Hedqvist B. Ocular allergic disorders and dry eye
disease: associations, diagnostic dilemmas, and management.
Acta  Ophthalmol  Scand  Suppl  2000;  230:32-7.  [PMID:
11057347]
5. Dogru M, Katakami C, Nakagawa N, Tetsumoto K, Yamamoto
M. Impression cytology in atopic dermatitis. Ophthalmology
1998; 105:1478-84. [PMID: 9709761]
6. Di Gioacchino M, Cavallucci E, Di Sciascio MB, Di Stefano F,
Verna N, Lobefalo L, Crudeli C, Volpe AR, Angelucci D,
Cuccurullo  F,  Conti  P.  Increase  in  CD45RO+  cells  and
activated  eosinophils  in  chronic  allergic  conjunctivitis.
Immunobiology 2000; 201:541-51. [PMID: 10834312]
7. Versura P, Maltarello MC, Caramazza R, Laschi R. Mucus
alteration  and  eye  dryness.  A  possible  relationship.  Acta
Ophthalmol (Copenh) 1989; 67:455-64. [PMID: 2801051]
8. Suzuki S, Goto E, Dogru M, Asano-Kato N, Matsumoto Y, Hara
Y, Fujishima H, Tsubota K. Tear film lipid layer alterations
in allergic conjunctivitis. Cornea 2006; 25:277-80. [PMID:
16633026]
9. Coyle PK, Sibony PA, Johnson C. Electrophoresis combined
with  immunologic  identification  of  human  tear  proteins.
Invest  Ophthalmol  Vis  Sci  1989;  30:1872-8.  [PMID:
2759802]
10. Gachon AM, Verrelle P, Betail G, Dastugue B. Immunological
and electrophoretic studies of human tear proteins. Exp Eye
Res 1979; 29:539-53. [PMID: 118888]
11. Kuizenga  A,  van  Haeringen  NJ,  Kijlstra  A.  SDS-Minigel
electrophoresis of human tears. Effect of sample treatment on
protein patterns. Invest Ophthalmol Vis Sci 1991; 32:381-6.
[PMID: 1993590]
12. Green-Church  KB,  Nichols  KK,  Kleinholz  NM,  Zhang  L,
Nichols JJ. Investigation of the human tear film proteome
using  multiple  proteomic  approaches.  Mol  Vis  2008;
14:456-70. [PMID: 18334958]
13. Nomura K, Takamura E. Tear IgE concentrations in allergic
conjunctivitis. Eye (Lond) 1998; 12:296-8. [PMID: 9683958]
14. Sainte Laudy J, Couturier P, Basset-Stheme D. Importance of
the lacrymal levels (total IgE, specific IgE and albumin) for
the study of allergic conjunctivitis. Allerg Immunol (Paris)
1994; 26:95-6. [PMID: 8185822]
15. Kari  O,  Salo  OP,  Bjorksten  F,  Backman  A.  Allergic
conjunctivitis, total and specific IgE in the tear fluid. Acta
Ophthalmol (Copenh) 1985; 63:97-9. [PMID: 3993353]
16. Li K, Chen Z, Duan F, Liang J, Wu K. Quantification of tear
proteins by SDS-PAGE with an internal standard protein. A
new method with special reference to small volume tears.
Graefes  Arch  Clin  Exp  Ophthalmol  2010;  248:853-62.
[PMID: 20127108]
17. Saari KM, Aho V, Paavilainen V, Nevalainen TJ. Group II
PLA(2)  content  of  tears  in  normal  subjects.  Invest
Ophthalmol Vis Sci 2001; 42:318-20. [PMID: 11157860]
18. Beers SA, Buckland AG, Koduri RS, Cho W, Gelb MH, Wilton
DC. The antibacterial properties of secreted phospholipases
A2: a major physiological role for the group IIA enzyme that
depends on the very high pI of the enzyme to allow penetration
of the bacterial cell wall. J Biol Chem 2002; 277:1788-93.
[PMID: 11706041]
19. Girgis DO, Dajcs JJ, O'Callaghan RJ. Phospholipase A2 activity
in normal and Staphylococcus aureus-infected rabbit eyes.
Invest  Ophthalmol  Vis  Sci  2003;  44:197-202.  [PMID:
12506075]
20. Nevalainen TJ, Graham GG, Scott KF. Antibacterial actions of
secreted phospholipases A2. Review. Biochim Biophys Acta
2008; 1781:1-9. [PMID: 18177747]
21. Chen D, Wei Y, Li X, Epstein S, Wolosin JM, Asbell P. sPLA2-
IIa is an inflammatory mediator when the ocular surface is
compromised.  Exp  Eye  Res  2009;  88:880-8.  [PMID:
19116146]
22. Mantelli  F,  Lambiase  A,  Bonini  S.  A  simple  and  rapid
diagnostic  algorithm  for  the  detection  of  ocular  allergic
diseases. Curr Opin Allergy Clin Immunol 2009; 9:471-6.
[PMID: 19638928]
23. Buckley RJ. Allergic eye disease–a clinical challenge. Clin Exp
Allergy 1998; 28:39-43. [PMID: 9988434]
24. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines
in human tear specimens in seasonal and chronic allergic eye
disease  and  in  conjunctival  fibroblast  cultures.  Clin  Exp
Allergy 2006; 36:777-84. [PMID: 16776679]
25. Yu M, Sun J, Peng W, Chen Z, Lin X, Liu X, Li M, Wu K.
Protein  expression  in  human  trabecular  meshwork:
downregulation of RhoGDI by dexamethasone in vitro. Mol
Vis 2010; 16:213-23. [PMID: 20161819]
26. Keane-Myers A. The pathogenesis of allergic conjunctivitis.
Curr Allergy Asthma Rep 2001; 1:550-7. [PMID: 11892084]
27. McGill JI, Holgate ST, Church MK, Anderson DF, Bacon A.
Allergic eye disease mechanisms. Br J Ophthalmol 1998;
82:1203-14. [PMID: 9924312]
28. Jakab  L.  Pathogenesis  of  different  forms  of  allergic
conjunctivitis.  Orv  Hetil  1999;  140:1438-9.  [PMID:
10489773]
29. Miyazaki D, Tominaga T, Yakura K, Kuo CH, Komatsu N,
Inoue Y, Ono SJ. Conjunctival mast cell as a mediator of
eosinophilic  response  in  ocular  allergy.  Mol  Vis  2008;
14:1525-32. [PMID: 18728750]
30. Acar N, Toker E, Kazokoglu H. Tear and serum eosinophil
cationic protein levels in seasonal allergic conjunctivitis. Eur
J Ophthalmol 2003; 13:671-5. [PMID: 14620169]
31. Montan PG, van Hage-Hamsten M. Eosinophil cationic protein
in  tears  in  allergic  conjunctivitis.  Br  J  Ophthalmol  1996;
80:556-60. [PMID: 8759270]
32. Li N, Wang N, Zheng J. X. Michael Liu, O. William Lever, Paul
M.  Erickson,  Liang  Li.  Characterization  of  Human  Tear
Proteome Using Multiple Proteomic Analysis Techniques. J
Proteome Res 2005; 4:2052-61. [PMID: 16335950]
33. Rapacz P, Tedesco J, Donshik PC, Ballow M. Tear lysozyme
and lactoferrin levels in giant papillary conjunctivitis and
vernal  conjunctivitis.  CLAO  J  1998;  14:207-9.  [PMID:
3147820]
34. Ballow M, Donshik PC, Rapacz P, Samartino L. Tear lactoferrin
levels in patients with external inflammatory ocular disease.
Invest Ophthalmol Vis Sci 1987; 28:543-5. [PMID: 3030955]
35. Dennis EA. Diversity of group types, regulation, and function
of  phospholipase  A2.  J  Biol  Chem  1994;  269:13057-60.
[PMID: 8175726]
Molecular Vision 2010; 16:2084-2091 <http://www.molvis.org/molvis/v16/a224> © 2010 Molecular Vision
209036. Fijneman RJ, Cormier RT. The roles of sPLA2-IIA (Pla2g2a)
in cancer of the small and large intestine. Front Biosci 2008;
13:4144-74. [PMID: 18508504]
37. Mayer  RJ,  Marshall  LA.  New  insights  on  mammalian
phospholipase A2(s); comparison of arachidonoyl-selective
and  -nonselective  enzymes.  FASEB  J  1993;  7:339-48.
[PMID: 8440410]
38. Adibhatla RM, Hatcher JF. Secretory phospholipase A2 IIA is
up-regulated by TNF-alpha and IL-1alpha/beta after transient
focal  cerebral  ischemia  in  rat.  Brain  Res  2007;
1134:199-205. [PMID: 17204250]
39. Lambeau  G,  Gelb  MH.  Biochemistry  and  physiology  of
mammalian secreted phospholipases A2. Annu Rev Biochem
2008; 77:495-520. [PMID: 18405237]
40. Menschikowski  M,  Hagelgans  A,  Siegert  G.  Secretory
phospholipase  A2  of  group  IIA:  is  it  an  offensive  or  a
defensive  player  during  atherosclerosis  and  other
inflammatory diseases? Prostaglandins Other Lipid Mediat
2006; 79:1-33. [PMID: 16516807]
Molecular Vision 2010; 16:2084-2091 <http://www.molvis.org/molvis/v16/a224> © 2010 Molecular Vision
The print version of this article was created on 11 October 2010. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
2091